Novartis AG's neuroscience franchise has been strengthened further with the company getting the green light from the European Commission to market Mayzent for the treatment of adults with secondary progressive multiple sclerosis (SPMS) with active disease.
The approval, which follows a positive opinion in November from the European Medicines Agency’s drug evaluation committee, the CHMP, was...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?